Kairos Pharma CEO to Present at LD Micro Invitational, Highlighting Clinical Progress
Kairos Pharma CEO Dr. John Yu will present at the LD Micro Invitational, providing updates on the company's clinical trials for ENV-105, a promising oncology candidate targeting drug resistance in cancer.
Kairos Pharma Ltd. (NYSE American: KAPA), a Los Angeles-based oncology therapeutics company, announced that its CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT. The event, held at the Luxe Sunset Boulevard Hotel in Los Angeles, will feature Dr. Yu providing an update on the company’s clinical program and partnering activities. This presentation is significant as it offers investors and industry stakeholders a glimpse into the progress of Kairos Pharma’s lead candidate, ENV-105, which aims to address critical unmet needs in cancer treatment.
Kairos Pharma is focused on overcoming drug resistance and immune suppression in cancer through structural biology. Its lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. These trials are aimed at addressing significant unmet medical needs, highlighting the potential impact of this novel therapeutic approach.
The presentation at the LD Micro Invitational comes at a crucial time for Kairos Pharma as it seeks to advance its clinical programs and explore partnering opportunities. The company’s focus on drug resistance is particularly relevant given that many cancers develop resistance to existing treatments, leading to disease progression and relapse. If successful, ENV-105 could offer a new avenue for patients who have limited options. For more details on the presentation, the full press release can be accessed at https://ibn.fm/g3aQY.
Kairos Pharma’s innovative approach underscores the growing importance of targeting resistance mechanisms in oncology. As of the date of the press release, ENV-105 has not been approved as safe or effective by the U.S. Food and Drug Administration or any comparable foreign regulator. However, the ongoing clinical trials represent a step forward in addressing critical gaps in cancer care. The company’s participation in the LD Micro Invitational provides a platform to communicate these developments to a broader audience, potentially attracting partners and investors interested in oncology innovation.
For the latest news and updates on Kairos Pharma, visit the company’s newsroom at https://ibn.fm/KAPA. This presentation is an opportunity for the investment community to gain insights into the company’s strategy and the potential of ENV-105 in transforming cancer treatment.